Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP’s Coronavirus Task Force Calls for Caution in Off-Year Re-Pricing Debate
June 26, 2020
- Keidanren Chief Cited Industry’s Concerns about Off-Year Re-Pricing at CEFP Confab, Minutes Reveal
June 26, 2020
- Japan OK for MSD’s 9-Valent HPV Vaccine Could Be Delayed after Deluge of Comments Hit Proposed Rule Changes
June 26, 2020
- MHLW Revokes Ninlaro’s Sakigake Status for AL Amyloidosis
June 26, 2020
- Ruling Party Members Mull Govt’s Stronger Control Functions for Infectious Diseases, with Future COVID-19 Measures in Mind
June 26, 2020
- AMED to Allocate 6.2 Billion Yen to BIKEN’s COVID-19 Vaccine Project: CiCLE Program
June 25, 2020
- AMED to Fund 29 New Research Projects to Develop COVID-19 Treatments, including 5 Company-Led Projects
June 24, 2020
- MHLW Grants Orphan Status to Venetoclax, 5 Other APIs
June 24, 2020
- MHLW to Hasten Electronic Scrip Rollout to Summer 2022: Health Minister
June 23, 2020
- Japan Likely to OK CureApp’s Smoking Cessation App in July
June 23, 2020
- Sakigake Status Awarded to GSK’s Next-Gen I/O Therapy, 2 More Drugs; System Possibly Subject to Review Next Time
June 22, 2020
- MHLW Council Determines High Medical Needs for 2 Antiemetics
June 22, 2020
- MHLW Delays Chuikyo Discussion Timeline for Off-Year Price Survey, Drops June-End Goal
June 22, 2020
- LDP Pharma Study Group Submits Proposal, Says Off-Year Re-Pricing Should Be Delayed
June 19, 2020
- First Generics for 18 APIs Join NHI Price List; Patent Row-Hit Edirol Gx, 7 AGs Included
June 19, 2020
- Chuikyo Doctor Reps Nix Drug Price Survey Discussion, Say It Should Only Come after Govt’s Go/No-Go Decision
June 18, 2020
- MHLW Plans to Introduce Scheme to Scrutinize Generic Makers’ Stable Supply Ability, Beginning with December Listing
June 18, 2020
- Orphan Status for Otsuka’s Sakigake-Designated Product, and 4 Other Cell and Gene Therapies Endorsed
June 18, 2020
- 0.1% of Tokyo Residents Test Positive for Coronavirus Antibodies: MHLW
June 17, 2020
- Label Revisions Ordered for Avastin, Memary
June 17, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…